
GHRS Stock Forecast & Price Target
GHRS Analyst Ratings
Bulls say
GH Research PLC has experienced a notable increase of approximately 22% in stock value, driven by positive developments related to its primary product candidate, GH001, which has shown promising efficacy and safety profiles in the treatment of Treatment-Resistant Depression (TRD). The company is poised to commence a global Phase 3 program for GH001 after receiving FDA approval to lift its clinical hold, paving the way for significant market opportunities and projected peak sales of over $1.4 billion in TRD alone. Additionally, positive endorsements regarding psychedelics from health officials, along with anticipated higher pricing for GH001 in line with competitors, bolster the company's outlook and support further growth potential.
Bears say
GH Research PLC faces significant headwinds that negatively impact its stock outlook, primarily due to potential delays in advancing its clinical trials and obtaining regulatory approvals for its mebufotenin therapies. The company may encounter challenges related to safety signals, adoption rates in a competitive market, and issues related to the efficacy of its product candidates as they progress through larger, longer trials. Additionally, as a clinical-stage biopharmaceutical company without current revenues, GH Research is vulnerable to risks associated with financing ongoing research and commercialization efforts, further complicating its path to market success.
This aggregate rating is based on analysts' research of GH Research PLC and is not a guaranteed prediction by Public.com or investment advice.
GHRS Analyst Forecast & Price Prediction
Start investing in GHRS
Order type
Buy in
Order amount
Est. shares
0 shares